Search

Displaying results 5171 - 5180 of 6198 in total
  1. Drug

    Navitoclax

    go.drugbank.com/drugs/DB12340
    Investigational

    Navitoclax is an orally bioavailable small molecule inhibitor of Bcl-2 family proteins. It is a substance being studied in the treatment of lymphomas and other types of cancer.

  2. Drug

    AG-702

    go.drugbank.com/drugs/DB05836
    Experimental

    This drug is developed by antigenics for the treatment of genital herpes infection and is under phase I of clinical trial.

  3. Drug

    Rosemary

    go.drugbank.com/drugs/DB14272
    Investigational

    It is not an approved drug.

  4. Drug

    RC118

    go.drugbank.com/drugs/DB18428
    Investigational

    RC118 is an antibody-drug conjugate that consists of a recombinant humanized IgG1 anti-Claudin18.2 monoclonal antibody conjugated to MMAE.

  5. Drug

    AT-GTX-502

    go.drugbank.com/drugs/DB17001
    Experimental

    AT-GTX-502 is an experimental, one-time gene therapy that uses AAV9 to deliver a functional copy of CLN3.

  6. Drug

    Doxapram

    go.drugbank.com/drugs/DB00561
    ApprovedInvestigationalVet approved

    A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225)

  7. Drug

    BMS-986251

    go.drugbank.com/drugs/DB19007
    Investigational

    BMS-986251 is under investigation in clinical trial NCT03329885 (A Study of Experimental Medication BMS-986251, Taken by Mouth, in Healthy Participants and Patients With Average to Very Serious Psoriasis

  8. Drug

    Nezastomig

    go.drugbank.com/drugs/DB19061
    Investigational

    Nezastomig is under investigation in clinical trial NCT06085664 (A Pilot Presurgical Trial of REGN5678 (Anti-psma X CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy

  9. Drug

    QL1706

    go.drugbank.com/drugs/DB17562
    Investigational

    QL1706 is an investigational bifunctional antibody that combines the activity of both PD-1 and CTLA-4 antibodies.

  10. Drug

    OptPA

    go.drugbank.com/drugs/DB18325
    Experimental

    Optimized tPA (OptPA; W253R/R275S-tPA) is an engineered variant of tPA designed to exhibit reduced neurotoxicity.[A261486]